Objective: This case-control study aimed to analyze the effect of intratympanic dexamethasone injection (ITDI) as a treatment option for patients with sudden sensorineural hearing loss (SSNHL) who were refractory to classic oral steroid treatment. Methods: Sixty-six patients with SSNHL, who were refractory to a course of oral steroid therapy, were included in this study. We prospectively treated consecutive 33 patients (34 ears) with ITDI from August 2002 to January 2004. We then retrospectively collected data from age-and sex-matched previous patients who did not take any more treatments after the initial regimen between March 2000 and July 2002. ITDI was performed in the supine position on four separate occasions over the course of 2 weeks. Hearing was assessed immediately before every injection and at 1 week after therapy. Hearing improvement was defined as more than 10 dB in pure-tone average (PTA). Results: Hearing improvement was observed in 13 (39.4%) of 33 patients who underwent ITDI and in two (6.1%) of 33 patients in the control group. Five of 13 represented hearing improvement over than 20 dB in PTA, and 11 of 20 patients, who showed no improvement in PTA by ITDI, showed improvement over 10 dB in some frequencies. There were no definite prognostic factors between the patients who responded to ITDI and those who did not. Conclusion: ITDI may be a simple and effective therapy for patients with refractory SSNHL.
INTRODUCTION
Sudden sensorineural HL (SSNHL), commonly described as an acute unilateral HL with tinnitus and vertigo, is reported to occur in five to 20 per 100,000. 1, 2 The etiology of SSNHL is idiopathic but viral infection, vascular compromise, disruption of cochlear membranes, immunologic diseases, and otologic tumors are discussed. 3, 4 The treatments of SSNHL are steroids, vasodilator, antiviral agents, diuretics, and low-salt diets. Spontaneous recovery rate without treatment ranges from 30% to 60%, most resolving within 2 weeks after onset. 5 It has been also known that this recovery rate is increased by several methods of treatment, including steroids. 1 High-dosage systemic steroid therapy is currently the mainstay of the treatment for SSNHL as a result of its high antiinflammatory effect, especially for moderate to severe HL. 1, 6 Despite oral steroid therapy for 2 weeks, either alone or in combination with other medications, the prognosis is not good for refractory patients. In fact, approximately 30% to 50% of patients show no response to any treatments. 1, 5 In these patients, high-dose steroid therapy may be sometimes applied for a long time, but it cannot be easily used because of side effects such as facial flush, edema, eruption, epistaxis, gastrointestinal trouble, liver function disorders, and glucose intolerance. 7 In addition, other alternative therapy has not been reported until now.
Intratympanic steroid injection is to introduce steroid through a tympanic membrane, resulting in reduced systemic steroid toxicity and higher perilymph steroid level selectively. 8, 9 In fact, Parnes et al. 10 reported that the recovery rate was 53% for 13 patients with SSNHL, and there are also other reports showing 38% to 72% of successful effects with intratympanic steroid injections. [11] [12] [13] However, in most of these reports, intratympanic steroid injection was used for first-line therapy for SSNHL, but not for second-line therapy for refractory SSNHL. 14, 15 So the purpose of this study is to evaluate the effect of intratympanic steroid injection in the patients with SSNHL who showed poor response to systemic steroid treatment.
MATERIALS AND METHODS
From March 2000 to January 2004, a case-controlled study was designed for 66 patients with idiopathic SSNHL who did not successfully respond to combination therapy, including oral steroid. The authors obtained an informed consent from patients and the present study was approved by the Institutional Review Boards of the Ajou University School of Medicine (Suwon, Korea). We collected prospectively the intratympanic dexamethasone in-jection (ITDI) group from August 2002 to January 2004. We treated consecutive 33 patients (34 ears) with ITDI in this period. We then retrospectively collected data from age-and sex-matched previous patients who did not take any more treatments after the initial regimen between March 2000 and July 2002. All patients underwent a history-taking, physical and audiologic examination, syphilis serology, autoimmune antibody test, and magnetic resonance imaging. We excluded the patients with SSNHL that might be caused by trauma, syphilis, Meniere's disease, tumors, and autoimmune diseases.
For all 66 subjects, standard treatments were initially performed with administration of oral steroids for 10 days, rest, stop smoking, low-salt diets, and some other medications. Oral steroid, prednisolone (Solondo; Yuhan Corp., Seoul, Korea) was used for 10 days on the schedule. Its schedule was that 60 mg per day for 5 days, 40 mg per day for 2 days, 20 mg per day for 2 days, and 10 mg per day for 1 day. Ginkgo biloba extracts (Tanamin; Yuyu Inc., Seoul, Korea), an antiviral intravenous agent, acyclovir (Vacrax; Samchulli Pharmaceutical Co., Seoul, Korea), and hydrochlorothiazide (Dichlozid; Yuhan Corp.) were sometimes used with the oral steroid.
ITDI was performed around 4 weeks after initial conservative treatments. After confirming the intact tympanic membrane, local anesthesia was done with lidocaine 10% pump spray (Xylocaine, 10-mg/dose; AstraZeneca Korea, Seoul, Korea). The procedure was performed at supine position under a microscope. Using a 25-gauge spinal needle and 1-mL syringe, one anterosuperior puncture was made for ventilation and another puncture was made at anteromiddle portion for perfusion. Dexamethasone (Dexamethasone, 5 mg/mL; Yuhan Corp.) was instilled through this site in the amount of 0.3 to 0.4 mL. The patient was instructed to avoid swallowing or moving in the supine position with the head tilted 45˚to the healthy side for 40 minutes. ITDI was applied twice a week for 2 consecutive weeks. Pure-tone audiometry was performed just before each injection and was followed 1 week after the last injection. Speech discrimination test (SDT) was also performed 1 week after the last injection. In the control group, pure-tone audiometry was performed 4 weeks and 8 weeks after initial conservative treatments, and speech discrimination test was also performed at the same time. However, some patients did not take SDTs at 8 weeks and were therefore excluded from this analysis.
Hearing improvement was defined as a decrease in the four-frequency (0.5, 1, 2, and 3 KHz) pure-tone average (PTA) of 10 dB or more or an increase in speech discrimination score (SDS) of 15% or more. Besides, the threshold difference was analyzed at each frequency in pure-tone audiometry. Side effects and subjective symptoms were analyzed also. Statistical analysis was performed using independent t-test, paired t-test, and 2 test. Significance was determined to be at the confidence level of P Ͻ .05.
RESULTS
The average age of the patients was 39.4 years in the ITDI group and 42.8 years in the control group. Male to female ratio was 13:20 in the ITDI group and 14:19 in the control group. Time of onset to therapy averaged 5.2 days in the ITDI group and 6.5 days in the control group. The initial level was average 72.0 Ϯ 23.4 dB PTA in the ITDI group and 76.5 Ϯ 28.7 dB in the control group. There were no statistical differences in age (P ϭ .096), sex ratio (P ϭ .977), time of onset to therapy (P ϭ .831), and initial hearing level (P ϭ .221) between the two groups (Table I) .
Objective Hearing Improvement
Comparing the clinical outcome between two groups, hearing improvement of 10 dB or more in PTA was noted in 13 (38.2%) of 34 ears and not noted in the remaining 21 ears in the ITDI group. In the control group, only two ears (6.1%) demonstrated improved hearing, whereas 29 ears (87.8%) showed no change of hearing threshold and two ears (6.1%) were aggravated ( Fig. 1) .
In the ITDI group, the mean value of PTAs before and after ITDI treatment were 72.0 Ϯ 23.4 dB and 62.9 Ϯ 22.5 dB, respectively, so that an improvement in mean PTA after ITDI was 9.1 dB showing statistical significance (P ϭ .001). In the control group, the mean value of PTAs at 4 weeks and 8 weeks after onset were 76.5 Ϯ 28.7 dB and 74.1 Ϯ 25.7 dB, respectively, so an improvement of the mean PTA was 2.4 dB. This difference was not statistically significant (Fig. 2) .
In the ITDI group, five ears had a hearing improvement of greater than 20 dB, whereas eight ears reported 10-to 20-dB gain. Eleven ears showed hearing gain more than 10 dB at some frequencies without an improvement of PTA (Fig. 3) . Table II shows hearing improvement in the patients treated with ITDI according to the response at initial treatments including oral steroid. There was no statistical significance (P ϭ .127) between seven patients (43.8%) who responded partially and six patients (33.3%) showing no response. Besides, Table III shows hearing improvement in the patients treated with ITDI according to PTAs before ITDI.
Analyzing hearing improvement on each frequency in ITDI group (34 ears), patients showing hearing improvement of 10 dB and more at low frequencies (0.25, 0.5, and 1 KHz), midfrequencies (2, 3 KHz), and high frequencies (4, 6, and 8 KHz) were 17 ears (50.0%), 12 ears (35.3%), and 13 ears (38.2%), respectively. These results showed that hearing improvement occurred more frequently at low frequencies (Fig. 4) .
In the ITDI group, the number of patients who showed hearing improvement at each injection was: 12 ears (35.3%) in the first injection, five ears (14.7%) in the second injection, four ears (11.8%) in the third injection, and seven ears (20.6%) in the fourth injection. The average injection for hearing improvement was 2.2 times.
Subjective Hearing Improvement
Among 20 patients in the ITDI group who had no change of hearing after ITDI, three patients felt hearing improvement subjectively and 10 patients answered decreased tinnitus. In addition, three patients reported sound was clarified. However, in the control group, only three of 31 patients who had no hearing gain reported that tinnitus was decreased.
Factors That Influence Hearing Improvement in the Intratympanic Dexamethasone Injection Group
We analyzed several prognostic factors between 13 patients (responsive group) who showed hearing gain after ITDI and 20 patients (nonresponsive group) who did not. The average age was 41.5 years in the responsive group and 37.7 years in the nonresponsive group. Male to female ratio in the responsive group and in the nonresponsive group were 2:10 and 10:11, respectively. The period from the onset of HL to starting initial treatments was 6.5 days in the responsive group and 4.7 days in the nonresponsive group. The period from the onset to starting ITDI was 31.8 days in the responsive group and 35.1 days in the nonresponsive group. There were no statistical differences. Before initial treatments, the mean value of initial hearing level was 92.1 Ϯ 23.5 dB PTA in the responsive group and 82.1 Ϯ 22.1 dB PTA in the nonresponsive group. Before ITDI, the mean of hearing levels in PTA in the responsive group and in the nonresponsive group were 77.7 Ϯ 19.4 dB and 68.5 Ϯ 25.4 dB, respectively. There were no statistical differences. After initial treatments before ITDI, there was a hearing gain in eight (61.5%) of 13 patients in the responsive group and nine (42.8%) of 21 patients in the nonresponsive group, but there was no statistical difference between them. In addition, there were no statistical differences in hearing pattern and existence of vertigo (Table IV) . DISCUSSION SSNHL, commonly described as an abrupt onset of hearing loss, generally within 3 days, of more than 30-dB hearing loss at three consecutive frequencies. 1 SSNHL is one of the diseases that etiology is not proven yet in Fig. 1 . Comparison of hearing improvement* between in the intratympanic dexamethasone injection (ITDI) group and in the control group. ITDI ϭ intratympanic steroid injection. *Hearing improvement means a decrease of 10 dB or more in pure-tone average (mean of 0.5, 1, 2, and 3 KHz). Fig. 2 . Comparison of hearing gain in PTA between in the ITDI group and in the control group. PTA ϭ pure-tone average; ITDI ϭ intratympanic dexamethasone injection; before PTA, before ITDI therapy; after, PTA at 4 weeks after ITDI therapy. *Comparison (paired t-test) between PTA at 4 weeks and 8 weeks after the onset of sudden sensorineural hearing loss (same interval to PTA follow-up in the ITDI group). otology, although several causes have been suggested, including vascular lesions, membrane breaks, and viral lesions. 3, 4 So the treatment for SSNHL may focus on the eradication of these etiologic factors or providing the inner ear environments that are good for hearing recovery.
Steroid therapy has been known the mainstay of treatment for SSNHL. 1, 5, 6, 16 There were a few reports concerning the effect of steroid treatment for SSNHL compared with placebo or no treatment. 1, 5, 6, 16 Mattox and Simmens 6 reported that 20 (71%) of 28 nontreated patients recovered their hearing "completely or at a good percentage," and 63 (72%) of 88 patients showed similar results after steroid therapy. In contrast, Wilson et al. 1 reported the beneficial effect of steroid in a prospective, randomized, double-blind study. Eleven (32%) of 34 placebo-treated patients recovered their hearing, and 20 (61%) of 33 steroid-treated patients, particularly those with moderate hearing loss, showed similar results. 1 Moskowitz et al. 6 demonstrated that there was hearing improvement in 24 (89%) of 27 patients with SSNHL when treated with steroid, but in four (44%) of nine patients in a control group. In addition, Veldman et al. 16 found that six (50%) of 12 patients showed effective responses to steroid treatment, whereas only six (32%) of 19 nontreated patients showed similar results. Conclusively, administration of systemic corticosteroids has become widely used for treatment of SSNHL and is arguably the treatment of choice. However, a few patients may experience adverse effects during systemic steroid therapy such as epistaxis, drug-induced abnormal liver function, acne, gastrointestinal trouble, gluteal abscess formation, and avascular necrosis. 7 Those who have hypertension or diabetic mellitus especially reach from 4.2% to 17.2% in SSNHL and pregnant women are known to be affected approximately 2.8% of the time with SSNHL. 2, 13 In these cases, systemic steroid treatment cannot help having limitations for use.
The alternative method is to increase the local concentration of steroids at the inner ear; also, low adverse effects of systemic steroids may be a direct steroid injection to the middle ear space. Actually, Parnes et al. 10 demonstrated in an experimental study using Guinea pigs that steroids (hydrocortisone, methylprednisolone, and dexamethasone) administered to the middle ear were able to achieve higher inner ear concentrations than when administered systemically. Similarly, Chandrasekhar 11 measured much higher perilymphatic concentration of dexamethasone when it was administered through a transtympanic route compared with systemic administration. She also compared different facilitating agents that may enhance transtympanic delivery. The addition of histamine together with dexamethasone significantly improved perilymphatic concentration of dexamethasone than other intravenous administration or dexamethasone only. Parnes et al. 10 also reported that methylprednisolone showed more effective absorption, but we used dexamethasone. In our experience, patients complained more burning sensation and pain when methylprednisolone and hydrocortisone were instilled than dexamethasone.
Various results about the effect of intratympanic steroid injection have been reported. Panes et al., 10 Chandraseckhar, 11 and Park et al. 13 reported relatively successful results with intratympanic steroid injection as an initial treatment option instead of systemic steroid therapy. Although these studies have some limitation of a small number of subjects, the effect of intratympanic steroid injection is approximately 53% to 72%, which is similar to that of systemic steroid therapy. For the patients who showed poor response to initial systemic steroid, Gianoli and Li 14 reported that just 44% of 22 patients responded to intratympanic steroid injection, but Kopke et al. 15 reported five of the six patients treated within 6 weeks of SSNHL improved word identification scores by using a round window membrane microcatheter.
We thought that intratympanic steroid injection may be more useful as a secondary treatment than an initial treatment, because it is not more effective than oral or intravenous administration and it is relatively inconvenient. Therefore, we tried ITDI for refractory patients with SNHL for the reason of advantages of avoiding side effects of systemic steroid therapy and increasing drug concentration locally. However, we do not know whether the effect is actually from intratympanic steroid, natural pathophysiological course, or delayed effect of systemic steroid treatment. For clarifying these effects, we started ITDI at around 4 weeks after initial treatment, that is, 2 weeks after the end of systemic steroid course, and we also analyzed the results comparing with those who did not receive any secondary treatments. However, this study has some limitation from the lack of a placebo-controlled study.
Ͼ20-dB
In this study, there was hearing improvement in 13 (38.2%) of 34 ears for refractory patients to systemic steroid therapy and in only two (6.6%) of 33 ears in the control group. This result is more similar to Gianoli and Li's report 14 15 might be an error because the number of subjects was not large enough. In this study, there was no significant difference in the hearing recovery rate of ITDI between those who slightly responded to initial systemic steroid therapy and those who did not show any response (Table II) . This means ITDI can be performed in refractory SSNHL regardless of the response to initial systemic steroids. The results of ITDI according to PTA before ITDI had not specific tendency, but there were relatively lots of hearing improvements in cases with severe HL (Table III) . So ITDI can be applied to those with severe HL.
On the other hand, 10 patients showed more than 10-dB hearing gain at some frequencies among 20 patients whose pure-tone averages did not improve. These 20 patients felt changed subjective symptoms such as hearing gain, decreased tinnitus, or cleared sound. These subjective symptoms might be influenced by hearing improvement at some frequencies regardless of improvement in PTA. Conclusively, there was much more hearing gain in the ITDI group (9.1 dB) than in the control group (2.4 dB) and more improvement of subjective symptoms in the ITDI group. This effect is considered not from the natural course of the disease, but ITDI.
Because the steroid from intratympanic injection penetrates through the round window to perilymph in cochlea, steroid may influence more to the basal turn than to the apex. So we had actually expected that hearing improvement might be in high frequencies (basal turn) than low frequencies (apical turn). However, in this study, 50% of hearing improvement (average 11.0 dB) occurred at low frequencies, whereas there was 34% to 38% of hearing gain (average 5.2-7.5 dB) in mid to high frequencies. From these results, ITDI may show more effective in the patients with HL in low frequencies. It is hypothesized that when the concentration of steroid in cochlea reaches a certain level, the recovery may easily occur at low frequencies than at high frequencies. This phenomenon may be explained by the difference in the damage threshold or the reversibility for recovery of hair cells according to the location. We can find some evidence of this hypothesis on the fact that hearing loss from noise, ototoxic drugs, or trauma is easily occurred in the high-tone, basal area of cochlea than in the apical area.
ITDI is a method that is performed with microscopic visualization under local anesthesia, maintaining the patient's position for 40 minutes. It needs a space and additional time for the procedure. Therefore, the proper injection times and interval must be determined, but not yet reported. In previous studies, Kopke et al. 15 continuously infused using a micropump for 14 days and Gianoli and Li 14 injected four times for 10 to 14 days. We evaluated also hearing change by checking pure-tone audiometry just before performing every injection. In the ITDI group, injection times that showed hearing recovery was 12 ears (35.3%) at the first time, five ears (14.7%) at the second time, four ears (11.8%) at the third time, and seven ears (20.6%) at the fourth time. From this result, we cannot determine the exact injection times, but we considered that injection may be needed more than four times at least.
The disadvantages of intratympanic steroid are known that temporary dizziness, ear drum perforation, and otitis media by stimulating middle ear mucosa. 11, 13, 14 In this study, only three patients showed temporary dizziness, which seemed to be caused by caloric effect of a drug and can be prevented with warming dexamethasone fluids.
Authors evaluated many prognostic factors to know which patients respond well to ITDI. We expected that ITDI would be more effective on patients (the responsive group) who responded to initial steroid treatment than those (the nonresponsive group) with no response. However, there was no significant difference between two Responsive group ϭ patients who showed hearing improvement of 10 dB or more in pure tone average with ITDI therapy; Nonresponsive group ϭ patients who showed no hearing improvement with ITDI therapy. * 2 test and independent t-test.
groups showing eight (61.5%) of 13 patients who responded to initial treatment and nine (42.8%) of 21 patients with no response improved their hearing after ITDI. Early response to initial systemic steroid did not influence the prognosis. There were also no statistical differences in age, sex, time of onset to treatment, initial hearing level, hearing pattern, and symptoms of vertigo between in the responsive group and the nonresponsive group.
CONCLUSION
ITDI may be a simple and effective treatment for the patients with SSNHL who are refractory to initial treatments, including systemic steroid therapy.
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